~~Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening.

Our 22,000 employees come to work every day with a common purpose: to develop and deliver breakthrough therapies that enable people with life-altering conditions to live their lives to the fullest.

At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.

Working together, the possibilities for our patients, healthcare partners and employees are unprecedented, with significant growth potential for our shareholders.

~~Shire’s Los Angeles facility is one of the world’s largest and most advanced plasma fractionation facilities. The facility features advanced technology to improve efficiency and quality in the processing of plasma proteins.

Employing approximately 1,800 people, the facility has 679,922 square feet of manufacturing space and recently added a new central hub that includes office space for support departments and a new cafeteria.
 
The facility has received numerous awards and recognition for its commitment to environmental health and safety, including Environmental Resources Management Certification and Validation Services (ERM/CVS) certification for ISO 14001. In 2010, the facility received certification to the OHSAS 180001 Occupation Health and Safety Assessment Series for health and safety management systems.